Future immunotherapy agents are likely to synergize with well-established antibodies for checkpoint blockade by enhancing infiltration with crucial immune cells such as activated Batf3 DCs and tumor-antigen-specific CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.